NPS Reclaims Rights to 2 Drugs From Takeda in $50M Stock Deal
By Catherine Shaffer
Tuesday, March 19, 2013
NPS Pharmaceuticals Inc. regained full worldwide rights to teduglutide (Gattex) and recombinant human parathyroid hormone 1-84 (PTH 1-84/Preotact) from Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, in exchange for common stock valued at $50 million, plus a milestone payment of $30 million in cash or stock in the first year that net sales of both products exceed $750 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.